<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2706245446
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ensutine
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BENDAMUSTINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        45
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1796.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DR. REDDY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DR. REDDY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bendamustine hydrochloride is a medicine which is used for the treatment of certain types of cancer (cytotoxic medicine).</p><p>Bendamustine hydrochloride is used alone (monotherapy) or in combination with other medicines for the treatment of the following forms of cancer:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic lymphocytic leukaemia in cases where fludarabine combination chemotherapy is not appropriate for you</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-Hodgkin&rsquo;s lymphomas, which had not, or only shortly, responded to prior rituximab treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multiple myeloma in cases where high-dose chemotherapy with autologous stem cell transplantation, thalidomide or bortezomib containing therapy is not appropriate for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Bendamustine hydrochloride:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to bendamustine hydrochloride or any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; while breastfeeding, if treatment with Bendamustine hydrochloride is necessary during lactation you must discontinue breastfeeding (see section warnings and precautions on breastfeeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver dysfunction (damage to the functional cells of the liver)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have yellowing of the skin or whites of the eyes caused by liver or blood problems (jaundice)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severely disturbed bone marrow function (bone marrow depression) and serious changes in your number of white blood cells and platelets in the blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had major surgical operations less than 30 days before starting treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an infection, especially one accompanied by a reduction in white blood cells (leucocytopenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with yellow fever vaccines.</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before using Bendamustine hydrochloride:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of reduced capability of the bone marrow to replace blood cells. You should have your number of white blood cells and platelets in the blood checked before starting treatment with Bendamustine hydrochloride, before each subsequent course of treatment and in the intervals between courses of treatment</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of infections. You should contact your doctor if you have signs of infection, including fever or lung symptoms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of reactions on your skin during treatment with Bendamustine hydrochloride. The reactions may increase in severity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in the mucous membrane (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in cases of existing heart disease (e.g. heart attack, chest pain, severely disturbed heart rhythms)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case you notice any pain in your side, blood in your urine or reduced amount of urine.</p><p>When your disease is very severe, your body may not be able to clear all the waste products from the dying cancer cells. This is called tumour lysis syndrome and can cause kidney failure and heart problems within 48 hours of the first dose of Bendamustine hydrochloride. Your doctor may ensure you are adequately hydrated and give you other medicines to help prevent it</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in case of severe allergic or hypersensitivity reactions. You should pay attention to infusion reactions after your first cycle of therapy.</p><p>At any time during or after your treatment, tell your doctor immediately if you notice or someone notices in you: memory loss, trouble thinking, difficulty walking or sight loss &ndash; these may be due to a very rare but serious brain infection which can be fatal (progressive multifocal leukoencephalopathy or PML).</p><p>Contact your doctor if you notice any suspicious skin changes because there may be an increased risk of certain types of skin cancer (non-melanoma skin cancer) with the use of this medicine.</p><p>&nbsp;</p><p><strong>Other medicines and Bendamustine hydrochloride</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.</p><p>If Bendamustine hydrochloride is used in combination with medicines which inhibit the formation of blood in the bone marrow, the effect on the bone marrow may be intensified.</p><p>If Bendamustine hydrochloride is used in combination with medicines which alter your immune response, this effect may be intensified.</p><p>Cytostatic medicines may diminish the effectiveness of live-virus vaccination. Additionally cytostatic medicines increase the risk of an infection after vaccination with live vaccines (e.g. viral vaccination).</p><p>&nbsp;</p><p><strong>Pregnancy, breastfeeding and fertility</strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.</p><p>&nbsp;</p><p><strong>Pregnancy</strong></p><p>Bendamustine hydrochloride can cause genetic damage and has caused malformations in animal studies. You should not use Bendamustine hydrochloride during pregnancy unless clearly indicated by your doctor. In case of treatment you should have medical consultation about the risk of potential adverse effects of your therapy for the unborn child and genetic consultation is recommended.</p><p>If you are a woman of childbearing potential you must use an effective method of contraception both before and during treatment with Bendamustine hydrochloride. If pregnancy occurs during your treatment with Bendamustine hydrochloride you must immediately inform your doctor and should have genetic consultation.</p><p>&nbsp;</p><p><strong>Breastfeeding</strong></p><p>Bendamustine hydrochloride must not be administered during breastfeeding. If treatment with Bendamustine hydrochloride is necessary during lactation you must discontinue breastfeeding. Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>Fertility</strong></p><p>Men receiving treatment with Bendamustine hydrochloride are advised not to father a child during treatment and for up to 6 months afterwards. Before starting treatment, you should seek advice on storing sperm because of the possibility of permanent infertility.</p><p>If you are a man, you should avoid fathering a child during treatment with Bendamustine hydrochloride and for up to 6 months after treatment has stopped.</p><p>There is a risk that treatment with Bendamustine hydrochloride will lead to infertility and you may wish to seek advice on storing of sperm before treatment starts.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Bendamustine hydrochloride has major influence on the ability to drive and to use machines. Do not drive or operate machines if you experience side effects, such as dizziness or lack of coordination.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bendamustine hydrochloride is administered into a vein over 30-60 minutes in various dosages, either alone (monotherapy) or in combination with other medicines.</p><p>Treatment should not be started if your white blood cells (leukocytes) and/or your blood platelets have fallen to counts below determined levels.</p><p>Your doctor will determine these values at regular intervals.</p><p>&nbsp;</p><p><strong>Chronic lymphocytic leukaemia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Bendamustine hydrochloride 100 mg per square meter of your body</p><p>surface area (based on your height and weight)</p></td><td style="vertical-align:top"><p>on Days 1+2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Repeat the cycle after 4 weeks up to 6 times</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Non-Hodgkin&rsquo;s lymphomas</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Bendamustine hydrochloride 120 mg per square meter of your body surface area (based on your height and weight)</p></td><td style="vertical-align:top"><p>on Days 1+2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Repeat the cycle after 3 weeks at least 6 times</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong>Multiple myeloma</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Bendamustine hydrochloride 120-150 mg per square meter of your body surface area (based on your height and weight)</p></td><td style="vertical-align:top"><p>on Days 1+2</p></td></tr><tr><td style="vertical-align:top"><p>Prednisone 60 mg per square meter of your body surface area (based on your height and weight) by injection or orally.</p></td><td style="vertical-align:top"><p>on Days 1-4</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Repeat the cycle after 4 weeks at least 3 times</p></td></tr></tbody></table><p>&nbsp;</p><p>Treatment should be terminated if white blood cell (leukocyte) and/or platelet values drop to determined levels. Treatment can be continued after white blood cell and platelet values have increased.</p><p>&nbsp;</p><p><strong>Impaired liver or kidney function</strong></p><p>Dependent on the degree of impairment of your liver function it may be necessary to adjust your dose (by 30% in case of moderate liver dysfunction). No dose adjustment is necessary in case of impairment of kidney function. Your attending doctor will decide whether a dosage adjustment is necessary.</p><p>&nbsp;</p><p><strong>How it is administered</strong></p><p>Treatment with Bendamustine hydrochloride should be undertaken only by doctors experienced in tumour therapy. Your doctor will give you the exact dose of Bendamustine hydrochloride and use the necessary precautions.</p><p>Your attending doctor will administer the solution for infusion after preparation as prescribed. The solution is administered into a vein as a short-term infusion over 30-60 minutes.</p><p>&nbsp;</p><p><strong>Duration of use</strong></p><p>There is no time limit laid down as a general rule for treatment with Bendamustine hydrochloride. Duration of treatment depends on disease and response to treatment.</p><p>&nbsp;</p><p>If you are at all worried or have any questions regarding treatment with Bendamustine hydrochloride, please speak to your doctor or nurse.</p><p>&nbsp;</p><p><strong>If you forget to use Bendamustine hydrochloride</strong></p><p>If a dose of Bendamustine hydrochloride has been forgotten, your doctor will usually retain the normal dosage schedule.</p><p>&nbsp;</p><p><strong>If you stop using Bendamustine hydrochloride</strong></p><p>The doctor treating you will decide whether to interrupt the treatment or to change over to a different preparation.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Some of the findings listed below may be found after tests performed by your doctor.</p><p>&nbsp;</p><p>Tissue decay (necrosis) has been observed very rarely following leakage of Bendamustine hydrochloride into the tissue outside the blood vessels (extravascular). A burning sensation where the infusion needle is inserted may be a sign of leakage outside the blood vessels. The consequence can be pain and poorly healing skin defects.</p><p>&nbsp;</p><p>The dose-limiting side-effect of Bendamustine hydrochloride is impaired bone-marrow function, which usually returns to normal after treatment.</p><p>&nbsp;</p><p>Suppressed bone marrow function may lead to low counts of blood cells, which in turn may lead to an increased risk of infection, anemia or a heightened risk of bleeding.</p><p>&nbsp;</p><p><strong>Very common side effects (may affect more than 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low counts of white blood cells (disease-fighting cells in your blood)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the red pigment of the blood (haemoglobin: a protein in red blood cells that carries oxygen throughout the body)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low counts of platelets (colourless blood cells that help blood clot)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infections</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mucosal inflammation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of creatinine (a chemical waste product that is produced by your muscle)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood level of urea (a chemical waste product)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatigue</p><p>&nbsp;</p><p><strong>Common side effects (may affect up to 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding (haemorrhage)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed metabolism caused by dying cancer cells releasing their contents into the blood</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stream</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (anemia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low counts of neutrophils (a common type of white blood cell important to fighting off infections)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reactions such as allergic inflammation of the skin (dermatitis), nettle rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (urticaria)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rise in liver enzymes AST/ALT (which may indicate inflammation or damage to cells in the liver)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rise in the enzyme alkaline phosphatase (an enzyme made mostly in the liver and bones)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a rise in bile pigment (a substance made during the normal breakdown of red blood cells)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low potassium blood levels (a nutrient that is necessary for the function of nerve and muscle cells, including those in your heart)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed function (dysfunction) of the heart&nbsp; (palpitations, angina pectoris)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed heart rhythms (arrhythmia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low or high blood pressure (hypotension or hypertension)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed lung function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore mouth (stomatitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin changes</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; missed periods (amenorrhoea)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; insomnia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash (urticaria)</p><p>&nbsp;</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accumulation of fluid in the heart sac (escape of fluid into the pericardial space)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ineffective production of blood cells in the bone marrow (the spongy material inside your bones where blood cells are made)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute leukemia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack, chest pain (myocardial infarct)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure</p><p>&nbsp;</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the blood (sepsis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic hypersensitivity reactions (anaphylactic reactions)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in your bone marrow function, which may make you feel unwell or show up in your blood tests</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs similar to anaphylactic reactions (anaphylactoid reactions)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of voice (aphonia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute circulatory collapse (failure of blood circulation mainly from a cardiac origin with failure to maintain the supply of oxygen and other nutrients to the tissues and removing toxins)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reddening of the skin (erythema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin (dermatitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching (pruritus)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash (macular exanthema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive sweating (hyperhidrosis)</p><p>&nbsp;</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; primary atypical inflammation of the lungs (pneumonia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; break-down of red blood cells</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rapid decrease in blood pressure sometimes with skin reactions or rash (anaphylactic shock)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbed sense of taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; altered sensations (paraesthesia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; malaise and pain in the limbs (peripheral neuropathy)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious condition resulting in the blockade of specific receptor in the nervous systems</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders of the nervous system</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack of coordination (ataxia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the brain (encephalitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased heart rate (tachycardia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the veins (phlebitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; formation of tissue in the lungs (fibrosis of the lungs)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding inflammation of the gullet (haemorrhagic oesophagitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding of stomach or gut</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infertility</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; multiple organ failure</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Not known side effects</strong> (cannot be estimated from the available data)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular and often rapid heart rate (atrial fibrillation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful red or purplish rash that spreads and blisters and/or other lesions begin to appear in</p><p>the mucous membranes (e.g. mouth and lips), in particular if you had before light sensitivity, infections of the respiratory system (e.g. bronchitis) and/or fever</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drug rash in combination therapy with rituximab</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from the lungs</p><p>&nbsp;</p><p>There have been reports of tumours (myelodysplastic syndrome, acute myeloid leukaemia (AML), bronchial carcinoma) following treatment with Bendamustine hydrochloride. No clear relationship with Bendamustine hydrochloride could be determined.</p><p>&nbsp;</p><p><strong>Contact your doctor or seek medical attention immediately</strong> if you notice any of the following side effects (frequency not known):</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious skin rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis. These can appear as reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widespread rash, high body temperature, enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label and the carton. The expiry date refers to the last day of that month.</p><p>Store and transport refrigerated (2-8&deg;C). Do not freeze.</p><p>Keep the container in the outer carton to protect the content from light.</p><p>&nbsp;</p><p><strong>Note on shelf-life after opening or preparing the solution </strong></p><p>Store and transport refrigerated (2-8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Bendamustine hydrochloride 180 mg/4 ml vial is a multi-use vial. Use within 28 days.</p><p>&nbsp;</p><p>From a microbiological point of view, the diluted solution should be used immediately after preparation.</p><p>&nbsp;</p><p>If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.</p><p>&nbsp;</p><p>Solutions for infusions prepared according to the directions listed at the end of this leaflet are stable in polyethylene bags for 3.5 hours at 25&deg;C/60% RH and 2 days at 2-8&deg;C. Bendamustine hydrochloride contains no preservatives. The solutions should not therefore be used after these lengths of time. It is the responsibility of the user to maintain aseptic conditions.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is bendamustine hydrochloride.</p><p>1 vial contains 180 mg of bendamustine hydrochloride (as monohydrate)</p><p>1 ml of the concentrate contains 45 mg bendamustine hydrochloride (as monohydrate).</p><p>The other ingredients are butylhydroxytoluene and Macrogol 300.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                5 ml amber glass vial with rubber stopper and flip-off seal.
The clear viscous solution appears pale yellow to yellow.
Bendamustine hydrochloride is available in pack sizes of 1 and 4 vials.
Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MARKETING AUTHORIZATION HOLDER: </strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad road, Building 8006- 4th Floor Riyadh, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p>Mailing: P.O. Box 12363 Riyadh, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Dr Reddys Laboratories Ltd , FTO 9</p><p>Plot No. Q1 to Q9, Phase - III, VSEZ,</p><p>Visakhapatnam District ,</p><p>Andhra Pradesh, 530 046, Duvvada,</p><p>INDIA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                06/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">دواء بنداموستين هيدروكلوريد هو دواء يستخدم لعلاج أنواع معينة من السرطان (دواء مُسمم للخلايا السرطانية).</p><p dir="RTL">يستخدم دواء بنداموستين هيدروكلوريد بمفرده (كعلاج أحادي) أو بمصاحبة أدوية أخرى لعلاج أنواع السرطانات التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم الليمفاوي المزمن، في الحالات التي يكون فيها العلاج الكيميائي المحتوي على فلودارابين، غير مناسب لها. &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الغدد المفاوية اللاهودجكيني، في الحالات التي لم تستجيب مُسبقًا للعلاج باستخدام دواء ريتوكسيماب أو استجابت فقط لفترة قصيرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم النقوى المتعدد، في الحالات التي يكون فيها العلاج الكيميائي باستخدام جرعات عالية متزامنًا مع زرع الخلايا الجذعية الذاتية أو الأنظمة العلاجية المحتوية على ثاليدوميد أو بورتيزوميب، غير مناسب لها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يُحظر عليك استخدام دواء بنداموستين هيدروكلوريد في الحالات التالية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية تجاه مادة بنداموستين هيدروكلوريد أو تجاه أي مكون من المكونات الأخرى الداخلة في تركيب هذا الدَّواء (المُدرجة في القسم رقم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنتِ تمارسين الرضاعة الطبيعية حيث إذا كان العلاج باستخدام دواء بنداموستين هيدروكلوريد ضروريًا أثناء ممارسة الرضاعة الطبيعية، فيجب عليكِ إيقاف الرضاعة الطبيعية (انظري قسم تحذيرات واحتياطات، الجزء الخاص بممارسة الرضاعة الطبيعية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور حاد في الكبد (تلف الخلايا الوظيفية في الكبد).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اصفرار الجلد أو الجزء الأبيض داخل العينين الناجم عن اضطرابات في الكبد أو الدم (يرقان).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب حاد في وظائف النخاع العظمي (قصور النخاع العظمي) واضطرابات خطيرة في عدد خلايا الدم البيضاء والصفائح الدموية في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا خضعت لإجراء أي عملية جراحية كبيرة قبل بدء العلاج بمدة تقل عن 30 يومًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى، وعلى وجه الخصوص عدوى مصحوبة بانخفاض في خلايا الدم البيضاء (قلة كرات الدم البيضاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إعطائك لقاح الحمى الصفراء بالتزامن مع استخدام الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات </strong></p><p dir="RTL">استشر الطبيب المعالج لك أو الصيدلي الخاص بك أو ﺍﻟﻣﻣﺭﺽ(ة) المتابع(ة) لحالتك قبل استخدام دواء بنداموستين هيدروكلوريد في الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة انخفاض قدرة النخاع العظمي على استبدال خلايا الدم. يجب فحص عدد كرات الدم البيضاء والصفائح الدموية في الدم قبل بدء العلاج باستخدام دواء بنداموستين هيدروكلوريد وقبل كل دورة علاجية تالية وفي الفترات الفاصلة بين الدورات العلاجية المتتابعة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بعدوى، يجب عليك الاتصال بالطبيب المعالج لك، إذا كنت تعاني من أعراض الإصابة بعدوى بما في ذلك الإصابة بحالات الحمى أو أعراض عدوى الرئة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة بأعراض وتفاعلات جلدية أثناء فترة العلاج باستخدام دواء بنداموستين هيدروكلوريد، حيث قد تزيد حدة التفاعلات الجلدية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة انتشار طفح جلدي أحمر أو أرجواني اللون مؤلم مصحوبًا بظهور بثور و/أو إصابات أخرى تظهر في الغشاء المخاطي (مثل الفم والشفتين)، وعلى وجه الخصوص إذا كنت قد عانيت مسبقًا من حساسية تجاه الضوء، وعدوى بالجهاز التنفسي (مثل التهاب الشعب الهوائية) و/أو حمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات الإصابة باضطرابات حالية في القلب (مثل نوبة قلبية ،آلم بالصدر وشدة اضطرابات في نبضات القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأي ألم في جانب الجسم لديك أو بنزول دم مع البول أو بانخفاض كمية البول.</p><p dir="RTL">في الحالات المرضية المتأخرة، قد لا يتمكن الجسم من التخلص من جميع بقايا الخلايا السرطانية التي تم القضاء عليها. ويسمى ذلك متلازمة انحلال الورم، وقد يؤدي إلى الإصابة بفشل كلوي واضطرابات في القلب في غضون 48 ساعة بعد أول جرعة من دواء بنداموستين هيدروكلوريد. قد يقوم الطبيب المعالج لك بالتأكد من ان &nbsp;نسبة السوائل في الجسم طبيعية، ويعطيك أدوية أخرى للوقاية من الإصابة بتلك الحالة. &nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الحساسية الشديدة أو تفاعلات فرط الحساسية، يجب ملاحظة التفاعلات الجانبية التىت قد تظهر اثناء التنقيط الوريدي بعد الدورة العلاجية الأولى.</p><p dir="RTL">أخبر الطبيب المعالج لك في أي وقت أثناء فترة العلاج أو بعدها إذا لاحظت أنك تعاني من الحالات التالية أو فى حالة لاحظ ذلك عليك شخص آخر : فقدان الذاكرة أو صعوبة بالتفكير أو صعوبة بالمشي أو فقدان البصر؛ فقد يكون ذلك ناجمًا عن الإصابة بعدوى دماغية نادرة جدًا ولكنها خطيرة، وقد تكون مهددة للحياة، (اعتلال بيضاء الدماغ متعدد البؤر المتقدم PML).</p><p dir="RTL">اتصل بالطبيب المعالج لك إذا عانيت من أي تغييرات مثيرة للريبة بالجلد ؛ حيث قد يزيد خطر الإصابة ببعض أنواع سرطانات الجلد (سرطان الجلد غير-الميلانومى) أثناء فترة استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>استخدام دواء بنداموستين هيدروكلوريد مع أدوية أخرى: &nbsp;</strong></p><p dir="RTL">أخبر الطبيب المعالج لك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">إذا تم استخدام دواء بنداموستين هيدروكلوريد بمصاحبة الأدوية التي تمنع تكون خلايا الدم في نخاع العظام، قد يكون تأثير الأدوية على نخاع العظام أكثر شدة،</p><p dir="RTL">إذا تم استخدام دواء بنداموستين هيدروكلوريد بمصاحبة الأدوية التي تُغير من استجابة جهاز المناعة في الجسم، قد يزداد تأثير الأدوية على جهاز المناعة</p><p dir="RTL">قد تقلل الأدوية المثبطة للخلايا السرطانية من فعالية التلقيح بالفيروسات الحية. كما تزيد الأدوية المثبطة للخلايا السرطانية من معدلات الإصابة بحالات العدوى عقب تلقي اللقاحات الحية (مثل اللقاحات الفيروسية).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الدواء أثناء الحمل والرَّضاعة الطبيعية والخصوبة:</strong></p><p dir="RTL">إذا كنتِ حاملًا أو تمارسين الرضاعة الطبيعة أو تعتقدين أنكِ حامل أو تخططين للحمل، فاستشيري الطبيب المعالج لكِ أو الصيدلي الخاص بكِ للحصول على النصيحة قبل استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الدواء أثناء فترة الحمل</strong></p><p dir="RTL">يمكن أن يسبب دواء بنداموستين هيدروكلوريد أضرارًا للجنين وقد تؤدي إلى حدوث تشوهات بالأجنة وفقًا للدراسات التي أُجريت على الحيوانات. يحظر استخدام دواء بنداموستين هيدروكلوريد أثناء فترة الحمل، ما لم يخبرك الطبيب المعالج لك بخلاف ذلك. وفي حالة العلاج باستخدام دواء بنداموستين هيدروكلوريد، يجب الحصول على استشارة من الطبيب المعالج لك عن مخاطر الآثار الجانبية المحتملة لهذا الدواء على الجنين كما ينصح بالحصول على استشارة أمراض وراثية.</p><p dir="RTL">إذا كنتِ سيدة قادرة على الحمل والإنجاب، يجب عليكِ استخدام وسائل فعالة لمنع الحمل قبل وأثناء فترة العلاج باستخدام دواء بنداموستين هيدروكلوريد. يجب عليكِ إبلاغ الطبيب المعالج لك فورًا، إذا حدث حمل أثناء فترة العلاج باستخدام دواء بنداموستين هيدروكلوريد، والحصول على استشارة أمراض وراثية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام الدواء أثناء فترة ممارسة الرضاعة الطبيعية</strong></p><p dir="RTL">يحظر استخدام دواء بنداموستين هيدروكلوريد أثناء ممارسة الرضاعة الطبيعية. يتعين عليكِ إيقاف ممارسة الرضاعة الطبيعية إذا كان العلاج باستخدام دواء بنداموستين هيدروكلوريد ضروريًا في هذه الفترة. استشيري الطبيب المعالج لكِ أو الصيدلي الخاص بكِ للحصول على النصيحة قبل استخدام أي علاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير الدواء على الخصوبة:</strong></p><p dir="RTL">يُنصح المرضى من الرجال، ممن يتم علاجهم باستخدام دواء بنداموستين هيدروكلوريد بعدم الإنجاب أثناء فترة العلاج ولمدة تصل إلى 6 أشهر عقب إيقاف استخدام الدواء. ويتعين عليك استشارة الطبيب المعالج لك قبل البدء في استخدام العلاج، للحصول على النصيحة الخاصة بحفظ الحيوانات المنوية، بسبب احتمالية الإصابة بالعقم الذي لا يمكن علاجه.</p><p dir="RTL">يحظر على المرضى من الرجال الإنجاب أثناء فترة العلاج بـاستخدام دواء بنداموستين هيدروكلوريد ولمدة تصل إلى 6 أشهر عقب إيقاف استخدام الدواء.</p><p dir="RTL">حيث قد يؤدي العلاج باستخدام دواء بنداموستين هيدروكلوريد إلى خطورة الإصابة بالعقم، وقد ترغب في استشارة الطبيب المعالج لك بشأن حفظ الحيوانات المنوية قبل بدء العلاج.</p><p dir="RTL"><strong>تأثير الدواء على قيادة السيارات واستخدام الآلات:</strong></p><p dir="RTL">يؤثر دواء بنداموستين هيدروكلوريد بشكل كبير على القدرة على قيادة السيارات واستخدام الماكينات والآلات.<br />يحظر عليك قيادة السيارات أو استخدام الماكينات، إذا كنت تعاني من هذه الآثار الجانبية مثل الإصابة بدوخة أو اختلال بالحركة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;يتم إعطاء دواء بنداموستين هيدروكلوريد في الوريد خلال فترة تتراوح من 30-60 دقيقة بجرعات مختلفة إما بمفرده (كعلاج أُحادي) أو بمصاحبة أدوية أخرى.</p><p dir="RTL">يحظر البدء في استخدام العلاج في حالة انخفاض عدد خلايا الدم البيضاء (كرات الدم البيضاء) و/أو الصفائح الدموية في الدم إلى معدل أقل من المستويات الطبيعية.</p><p dir="RTL">سيتابع الطبيب المعالج لك مستويات خلايا الدم على فترات منتظمة أثناء استخدام العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدام الدواء لعلاج سرطان الدم الليمفاوي المُزمِن</strong>:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُستخدم دواء بنداموستين هيدروكلوريد بجرعة 100 مجم /لكل متر مربع من مساحة سطح الجسم (وفقًا لطول ووزن الجسم).</p></td><td style="vertical-align:top"><p dir="RTL">في الأيام 1 + 2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">تُكرر الدورة العلاجية بعد 4 أسابيع حتى 6 مرات.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدام الدواء لعلاج سرطان الغدد الليمفاوية اللاهودجكيني:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُستخدم دواء بنداموستين هيدروكلوريد بجرعة 120 مجم/ لكل متر مربع من مساحة سطح الجسم (بناءً على الطول والوزن).</p></td><td style="vertical-align:top"><p dir="RTL">في الأيام 1 + 2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">تُكرر الدورة العلاجية بعد 3 أسابيع حتى 6 مرات على الأقل.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استخدام الدواء لعلاج الورم النقوى المتعدد</strong>:</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">يُستخدم دواء بنداموستين هيدروكلوريد بجرعة 120-150 مجم/ لكل متر مربع من مساحة سطح الجسم (بناءً على الطول والوزن).</p></td><td style="vertical-align:top"><p dir="RTL">في الأيام 1 + 2</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">يستخدم بريدنيزون بجرعة 60 مجم/ لكل متر مربع من مساحة سطح الجسم (بناءً على الطول والوزن) عن طريق الحقن أو أقراص للتناول عن طريق الفم.</p></td><td style="vertical-align:top"><p dir="RTL">في الأيام 1 + 4</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">تُكرر الدورة العلاجية بعد 4 أسابيع ولعدد 3 مرات على الأقل.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إيقاف العلاج في حالة انخفاض عدد خلايا الدم البيضاء (كرات الدم البيضاء) و/أو مستويات الصفائح الدموية عن المستويات الطبيعية. يمكن الاستمرار في استخدام العلاج بعد عودة عدد خلايا الدم البيضاء والصفائح الدموية الى المستويات الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تُعاني من قصور في وظائف الكبد أو الكلى:</strong></p><p dir="RTL">قد يكون من الضروري، وفقًا لدرجة قصور وظائف الكبد، تعديل الجرعة (بنسبة 30٪ في حالة الإصابة بقصور متوسطة في وظائف الكبد)، وليس من الضروري تعديل الجرعة في حالة الإصابة بقصور في وظائف الكلى؛ وسيقرر الطبيب المعالج لك ما إذا كان يلزم تعديل الجرعة أم لا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>كيفية استخدام دواء بنداموستين هيدروكلوريد:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن يتم إعطاء العلاج باستخدام دواء بنداموستين هيدروكلوريد فقط من قبل الأطباء ذوي الخبرة في علاج الأورام. سيعطيك الطبيب المعالج لك الجرعة المناسبة لك من دواء بنداموستين هيدروكلوريد مع اتخاذ الاحتياطات اللازمة.</p><p dir="RTL">سيعطيك الطبيب المعالج لك المحلول المُعد للحقن بالتنقيط داخل الوريد بعد التحضير كما هو موصوف. يتم إعطائك المحلول في الوريد كمحلول قصير المدة عبر التنقيط الوريدي خلال فترة تتراوح من 30 إلى 60 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مدة الاستخدام:</strong></p><p dir="RTL">لا يوجد فترة زمنية محدد كقاعدة عامة للعلاج باستخدام دواء بنداموستين هيدروكلوريد. تختلف مدة العلاج وفقًا لشدة المرض الذي يتم علاجه ومدى استجابتك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مع الطبيب المعالج لك أو الممرض(ة) المتابع(ة) لحالتك إذا كنت قلقًا بشأن أي شيء أو إذا كانت لديك أية أسئلة أخرى تتعلق بالعلاج باستخدام دواء بنداموستين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام دواء بنداموستين هيدروكلوريد:</strong></p><p dir="RTL">إذا نسيت استخدام دواء بنداموستين هيدروكلوريد، سيلتزم الطبيب المعالج لك عادةً بالجدول الزمني للجرعة العادية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام دواء بنداموستين هيدروكلوريد</strong></p><p dir="RTL">سيقرر الطبيب المعالج لك ما إذا كان يجب عليك إيقاف العلاج بهذا الدواء مؤقتًا أو استخدام دواء من نوع مختلف.</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى حول استخدام هذا الدواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يُسبب هذا الدواء، مثله مثل كافة الأدوية، آثارًا جانبية على الرغم من عدم حدوثها لجميع المرضى.</p><p dir="RTL">يمكن الحصول على بعض النتائج المذكورة أدناه عقب إجراء الفحوصات المُحددة من قبل الطبيب المعالج لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لوحظ حدوث تحلل للأنسجة (نخر أو موت الأنسجة) بشكل نادر جدًا بعد تسرب دواء بنداموستين هيدروكلوريد إلى الأنسجة المحيطة بالأوعية الدموية. قد يكون الشعور بحرقان في موضع إدخال إبرة الحقن بالتنقيط الوريدي أحد أعراض تسرب الدواء خارج الأوعية الدموية. وقد يؤدي ذلك إلى الشعور بألم وعدم التئام جروح الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتمثل الآثار الجانبية التي تؤدي إلى تقليل الجرعة العلاجية من دواء بنداموستين هيدروكلوريد مثل: انخفاض وظائف النخاع العظمي وعادة ما يتم رجوعها للمعدل الطبيعي عقب إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي الإصابة بقصور في وظائف النخاع العظمي إلى انخفاض عدد خلايا الدم المتكونة، مما ينجم عنه زيادة معدلات خطر التعرض للإصابة بفقر الدم أو زيادة خطر التعرض للنزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة جدًا (قد تُؤثر على أكثر من مريض واحد من بين كل 10&nbsp;مرضى):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (خلايا الدم المسئولة عن مقاومة الأمراض).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في صبغة الدم الحمراء (هيموجلوبين: بروتين في خلايا الدم الحمراء يحمل الأكسجين إلى جميع أجزاء الجسم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية (خلايا دم عديمة اللون تساعد في تجلط الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بحالات عدوى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بإعياء (غثيان).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء المخاطي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى الكرياتينين في الدم (بقايا كيميائية تفرزها العضلات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى اليوريا في الدم (بقايا الدواء الكيميائي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 10&nbsp;مرضى).</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف (نزيف دم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأيض الناجمة عن تحلل بقايا الخلايا السرطانية الميتة في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض خلايا الدم الحمراء الذي يسبب شحوب البشرة مما يؤدي إلى ضعف أو ضيق بالتنفس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنيميا (فقر دم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا العدلات (نوع شائع من خلايا الدم البيضاء يعتبر مهمًا في محاربة العدوى).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية مثل التهاب الجلد التحسسي (التهاب الجلد)، طفح جلدي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;(شرى).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع في إنزيمات الكبد، إنزيم ناقلة أمين الأسبارتات / ناقلة أمين الألانين (التي تشير إلى التهاب أو تلف خلايا بالكبد).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع إنزيم الفوسفاتاز القلوي (إنزيم يُفرز بشكل كبير في الكبد والعظام).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الصبغة الصفراء (مادة تُفرز أثناء الانخفاض الطبيعي لخلايا الدم الحمراء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات بوتاسيوم الدم (مادة مغذية تقوي وظيفة الخلايا العصبية والعضلية وتشمل الخلايا الموجودة في القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في وظائف القلب (خفقان، ذبحة صدرية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في نظم القلب (عدم انتظام ضربات القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض أو ارتفاع ضغط الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في وظائف الرئة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة الفم (التهاب الفم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع الطمث (توقف فترة الحيض).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي يصاحبه حكة (شرى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 100 مريض) </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تراكم السوائل في تجويف القلب (خروج السائل في منطقة التامور).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم فعالية إفراز خلايا الدم في نخاع العظم (المادة الإسفنجية داخل العظام حيث تُفرز خلايا الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم الحاد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبة قلبية، ألم بالصدر (احتشاء عضلة القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلْب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 1,000 مريض).</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى بالدم (تعفن الدم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية الشديدة (تفاعلات الحساسية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض وظائف نخاع العظم مما يؤدي إلى الشعور بتعب أو قد تظهر في اختبارات الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشابهة لتفاعلات الحساسية (تفاعلات تأقية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خمول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الصوت (أفونيا).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوط حاد بالدورة الدموية (قصور حاد بالدورة الدموية الذي يكون بشكل رئيسي من القلب مع الفشل في الحفاظ على إمدادات الأكسجين والمواد المغذية الأخرى إلى الأنسجة وإزالة السموم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار البشرة (حمامي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد (التهابات جلدية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة جلدية (هرش بالجلد).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي (بقع جلدية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إفراز العرق (فرط التعرق).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية نادرة جدًا (قد تُؤثر على ما يصل إلى مريض واحد من بين كل 10,000&nbsp;مريض):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب أولي غير طبيعي في الرئتين (التهاب رئوي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض خلايا الدم الحمراء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض سريع في ضغط الدم قد يصاحبه في بعض الأحيان تفاعلات جلدية أو طفح جلدي (صدمة تأقية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في حاسة التذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير الإحساس (مَذَل).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وعكة وألم في الأطراف (اعتلال الأعصاب المحيطية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة خطيرة تؤدي إلى إحصار مستقبلات معينة في الجهاز العصبي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بالجهاز العصبي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اختلال بالحركة (رَنح).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الدماغ (التهابات بالدماغ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة معدل ضربات القلب (سرعة ضربات القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة الدموية (التهاب وريدي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكون الأنسجة في الرئتين (تليف الرئتين).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب مصحوب بنزيف في المريء (التهاب المريء النزفي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف بالمعدة أو الأمعاء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بعقم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل العديد من أجهزة الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية غير معروف معدل تكرارها</strong> (لا يُمكن تقدير مُعدَّل التكرار من واقع البيانات المتاحة):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل بالكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل بالكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب وسرعتها (رجفان أذيني).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار طفح جلدي أحمر أو أرجواني اللون مؤلم وظهور بثور و/أو إصابات أخرى في الغشاء المخاطي (مثل الفم والشفتين)، وعلى وجه الخصوص إذا عانيت مسبقًا من حساسية تجاه الضوء وعدوى بالجهاز التنفسي (مثل التهاب الشعب الهوائية) و/أو حمى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح دوائي في حالة استخدام العلاج بالتزامن مع دواء ريتوكسيماب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب رئوي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الرئتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حالات الإصابة بأورام (متلازمة خلل التنسج النخاعي وسرطان الدم النخاعي الحاد وسرطان القصبات الهوائية) بعد العلاج باستخدام دواء بنداموستين هيدروكلوريد. لا توجد علاقة واضحة بين الإصابة بالأورام واستخدام دواء بنداموستين هيدروكلوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بالطبيب المعالج لك أو احصل على العناية الطبية على الفور إذا لاحظت أيًا من الآثار الجانبية التالية </strong>(معدل تكرارها غير معروف):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، ويشمل متلازمة ستيفنز جونسون وتقَشُّر الأنسجة المُتموِّتَة البَشروِية التسممي. يمكن أن يظهر الطفح الجلدي على شكل بقع حمراء تشبه منطقة الهدف (النشان) أو بقع دائرية في كثير من الأحيان يصاحبها ظهور بثور مركزية على الساق، تقشر الجلد، تقرحات الفم والحلق والأنف والأعضاء التناسلية والعين ويمكن أن يسبقها أعراض حمى وأعراض شبيهة بأعراض الإنفلونزا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتشار طفح جلدي وارتفاع درجة حرارة الجسم، وتضخم الغدد الليمفاوية وتأثُر أعضاء الجسم الأخرى (متلازمة رد الفعل الدوائي مع فرط الحمضات والأعراض الجهازية وتُعرف اختصارًا (DRESS)).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية:</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب المعالج لك أو مقدم الرعاية الصحية المتابع لحالتك أو الصيدلي الخاص بك، إذا أصبح أيٌ من هذه الآثار الجانبية خطيرًا أو إذا عانيت من أية آثار جانبية غير المُدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول ورؤية الأطفال.</p><p dir="RTL">يُحظر استخدام هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الملصق والعبوة الكرتونية. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يُحفظ ويُنقل بعد التبريد في درجة حرارة تتراوح من 2&deg; إلى 8&deg; درجة مئوية. يُحظر تعريض الدواء للتجميد</p><p dir="RTL">وتُحفظ الزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL"><strong>ملاحظات حول فترة الصلاحية بعد فتح الزجاجة أو تحضير المحلول: </strong></p><p dir="RTL">يُحفظ الدواء ويُنقل بعد التبريد في درجة حرارة تتراوح من 2&deg; إلى 8&deg; درجة مئوية. يُحظر تعريض الدواء للتجميد، وتحفظ الزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من التعرّض للضوء.</p><p dir="RTL">يتوفر دواء بنداموستين هيدروكلوريد 180 مجم/4 مل في زجاجة متعددة الاستخدامات. يستخدم هذا الدواء في غضون ٢٨ يومًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام المحلول المخفف فورًا بعد تحضيره، وفقًا لوجهة النظر الميكروبيولوجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم يُستخدَم الدواء على الفور، تقع مسئولية مدة حفظ الدواء وشروط الحفظ قبل الاستخدام على عاتق المستخدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تٌحفظ المحاليل التي تم إعدادها للتنقيط داخل الوريد وفقًا للإرشادات المذكورة في نهاية هذه النشرة، في عبوات مصنوعة من البولي إيثيلين لمدة 3.5 ساعة عند درجة حرارة: 25&deg; درجة مئوية / 60٪ رطوبة نسبية، ولمدة يومين في درجة حرارة تتراوح من 2&deg; إلى 8&deg; درجة مئوية. لا يحتوي دواء بنداموستين هيدروكلوريد على مواد حافظة؛ لذا، لا ينبغي استخدام المحلول المحضر عقب انتهاء المدد الزمنية المحددة. تقع مسئولية حفظ المحلول المحضر في ظروف مُعقمة على عاتق المستخدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;لا ينبغي التخلص من الأدوية عبر إلقائها في مياه الصرف أو المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تحتاج إليها؛ حيث ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي: بنداموستين هيدروكلوريد</p><p dir="RTL">تحتوي الزجاجة الواحدة على 180 مجم من بنداموستين هيدروكلوريد (في شكل بنداموستين هيدروكلوريد أحادي الهيدرات).</p><p dir="RTL">يحتوي كل 1 مل مُركز على 45 مجم من بنداموستين هيدروكلوريد (في شكل بنداموستين هيدروكلوريد أحادي الهيدرات).</p><p dir="RTL">تشتمل المكونات الأخرى على بوتيل هيدروكسي تولوين وماكروجول 300.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتوفر الدواء في زجاجة بسعة 5 مل مصنوعة من الزُجاجٌ الكَهْرَمانِيّ (غامق اللون)، ومغلقة بسدادة مطاطية وغطاء قابل للنزع.</p><p dir="RTL">يتراوح لون المحلول اللزج الشفاف من اللون الأصفر الباهت إلى اللون أصفر.</p><p dir="RTL">يتوفر دواء بنداموستين هيدروكلوريد في عبوات بأحجام 1 و4 زجاجات.</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات في الدولة التي تعيش فيها.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;مالك حق التصريح بالتسويق: </strong></p><p dir="RTL">شركة سدير فارما (SPC)</p><p dir="RTL">طريق الملك فهد، مبنى 8006 - الدور الرابع، الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف: 920001432-11-966+</p><p dir="RTL">فاكس: 4668195-11-966+</p><p dir="RTL">البريد الإلكتروني: <u>info@sudairpharma.com</u></p><p dir="RTL">عنوان المراسلة: صندوق بريد رقم: 12363، الرياض، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">شركة مختبرات دكتور ريدي، ليمتد، (FTO 9)</p><p dir="RTL">قطعة رقم كيو 1 إلى كيو 9، المرحلة الثالثة، منطقة فيشاخاباتنام الاقتصادية الخاصة</p><p dir="RTL">مدينة فيساخاباتنام،</p><p dir="RTL">ولاية أندرا براديش، 530046، دوفادا</p><p dir="RTL">الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ensutine 180 mg/4 ml Concentrate For Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 180 mg bendamustine hydrochloride (as monohydrate).
1 ml of the concentrate contains 45 mg bendamustine hydrochloride (as monohydrate).

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion
Clear, pale yellow to yellow viscous solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.</p><p>Indolent non-Hodgkin&#39;s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.</p><p>Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><strong><em>Monotherapy for chronic lymphocytic leukaemia</em></strong></p><p>100 mg/m<sup>2</sup>&nbsp;body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks, up to 6 times.</p><p><strong><em>Monotherapy for indolent non-Hodgkin&#39;s lymphomas refractory to rituximab</em></strong></p><p>120 mg/m<sup>2</sup>&nbsp;body surface area bendamustine hydrochloride on days 1 and 2; every 3 weeks for at least 6 times</p><p><strong><em>Multiple myeloma</em></strong></p><p>120 - 150 mg/m<sup>2</sup>&nbsp;body surface area bendamustine hydrochloride on days 1 and 2, 60 mg/m<sup>2</sup>&nbsp;body surface area prednisone i.v. or per os on days 1 to 4; every 4 weeks for at least 3 times.</p><p><strong><em>Hepatic impairment</em></strong></p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impairment (serum bilirubin &lt; 1.2 mg/dl). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum bilirubin 1.2 - 3.0 mg/dl).</p><p>No data is available in patients with severe hepatic impairment (serum bilirubin values of &gt; 3.0 mg/dl)</p><p><strong><em>Renal impairment</em></strong></p><p>On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of &gt; 10 ml/min. Experience in patients with severe renal impairment is limited.</p><p><strong><em>Paediatric population</em></strong></p><p>The safety and efficacy of bendamustine hydrochloride in children have not yet been established. Current available data is not sufficient to make a recommendation on posology.</p><p><strong><em>Elderly patients</em></strong></p><p>There is no evidence that dose adjustments are necessary in elderly patients</p><p><strong><u>Method of administration</u></strong></p><p>For intravenous infusion over 30 - 60 minutes</p><p>Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.</p><p>Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and/or platelet values have dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively</p><p>Treatment should be terminated or delayed if leukocyte and/or platelet values have dropped to &lt; 3,000/&micro;l or &lt; 75,000/&micro;l, respectively. Treatment can be continued after leukocyte values have increased to &gt; 4,000/&micro;l and platelet values to &gt; 100,000/&micro;l.</p><p>The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended.</p><p>In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.</p><p>If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.</p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- During breast-feeding
- Severe hepatic impairment (serum bilirubin > 3.0 mg/dl)
- Jaundice
- Severe bone marrow suppression and severe blood count alterations (leukocyte and/or platelet values dropped to < 3,000/µl or < 75,000/µl, respectively)
- Major surgery less than 30 days before start of treatment
- Infections, especially involving leukocytopenia
- Yellow fever vaccination
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myelosuppression</strong></p><p>Patients treated with bendamustine hydrochloride may experience myelosuppression. In the event of treatment-related myelosuppression, leukocytes, platelets, haemoglobin, and neutrophils must be monitored at least weekly. Prior to the initiation of the next cycle of therapy, the following parameters are recommended: Leukocyte and/or platelet values &gt; 4,000/&micro;l or &gt; 100,000/&micro;l, respectively.</p><p><strong>Infections</strong></p><p>Serious and fatal infections have occurred with bendamustine hydrochloride, including bacterial (sepsis, pneumonia) and opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP), varicella zoster virus (VZV) and cytomegalovirus (CMV). Cases of progressive multifocal leukoencephalopathy (PML) including fatal ones have been reported following the use of bendamustine mainly in combination with rituximab or obinutuzumab. Treatment with bendamustine hydrochloride may cause prolonged lymphocytopenia (&lt; 600/&mu;l) and low CD4-positive T-cell (T-helper cell) counts (&lt; 200/&mu;l) for at least 7&ndash;9 months after the completion of treatment. Lymphocytopenia and CD4-positive T-cell depletion are more pronounced when bendamustine is combined with rituximab. Patients with lymphopenia and low CD4-positive T-cell count following treatment with bendamustine hydrochloride are more susceptible to (opportunistic) infections. In case of low CD4-positive T-cell counts (&lt; 200 &micro;/l) Pneumocystis jirovecii pneumonia (PJP) prophylaxis should be considered. All patients should be monitored for respiratory signs and symptoms throughout treatment. Patients should be advised to report new signs of infection, including fever or respiratory symptoms promptly. Discontinuation of bendamustine hydrochloride should be considered if there are signs of (opportunistic) infections.</p><p>Consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioural signs or symptoms. If PML is suspected then appropriate diagnostic evaluations should be undertaken and treatment suspended until PML is excluded.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Hepatitis B reactivation</strong></p><p>Reactivation of hepatitis B in patients who are chronic carriers of this virus has occurred after these patients received bendamustine hydrochloride. Some cases resulted in acute hepatic failure or a fatal outcome. Patients should be tested for HBV infection before initiating treatment with bendamustine hydrochloride. Experts in liver disease and in the treatment of hepatitis B should be consulted before treatment is initiated in patients with positive hepatitis B tests (including those with active disease) and for patients who test positive for HBV infection during treatment. Carriers of HBV who require treatment with bendamustine hydrochloride should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.</p><p><strong>Skin reactions</strong></p><p>A number of skin reactions have been reported. These events have included rash, severe cutaneous reactions and bullous exanthema. Cases of Stevens &ndash; Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), some fatal, have been reported with the use of bendamustine hydrochloride. Patients should be advised of the signs and symptoms of these reactions by their prescribers and should be told to seek medical attention immediately if they develop these symptoms. Some events occurred when bendamustine hydrochloride was given in combination with other anticancer agents, so the precise relationship is uncertain. When skin reactions occur, they may be progressive and increase in severity with further treatment. If skin reactions are progressive, bendamustine should be withheld or discontinued. For severe skin reactions with suspected relationship to bendamustine hydrochloride, treatment should be discontinued.</p><p><strong>Non-melanoma skin cancer</strong></p><p>In clinical studies, an increased risk for non-melanoma skin cancers (basal cell carcinoma and squamous cell carcinoma) has been observed in patients treated with bendamustine containing therapies. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.</p><p><strong>Cardiac disorders</strong></p><p>During treatment with bendamustine hydrochloride the concentration of potassium in the blood of patients with cardiac disorders must be closely monitored and potassium supplement must be given when K<sup>+</sup>&nbsp;&lt;3.5 mEq/l and ECG measurement must be performed.</p><p>Fatal cases of myocardial infarction and cardiac failure have been reported with bendamustine hydrochloride treatment. Patients with concurrent or history of cardiac disease should be observed closely.</p><p><strong>Nausea, vomiting</strong></p><p>An antiemetic may be given for the symptomatic treatment of nausea and vomiting.</p><p><strong>Tumour lysis syndrome</strong></p><p>Tumour lysis syndrome (TLS) associated with bendamustine treatment has been reported in patients in clinical trials. The onset tends to be within 48 hours of the first dose of bendamustine and, without intervention, may lead to acute renal failure and death. Preventive measures such as adequate hydration , close monitoring of blood chemistry, particularly potassium and uric acid levels, and the use of hypouricemic agents (allopurinol and rasburicase) should be considered prior to therapy. There have been a few cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis reported when bendamustine and allopurinol are administered concomitantly.</p><p><strong>Anaphylaxis</strong></p><p>Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms are generally mild and include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred. Patients must be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids must be considered in subsequent cycles in patients who have previously experienced infusion reactions.</p><p>Patients who experienced Grade 3 or worse allergic-type reactions were typically not re-challenged.</p><p><strong>Contraception</strong></p><p>Bendamustine hydrochloride is teratogenic and mutagenic.</p><p>Women should not become pregnant during treatment. Male patients should not father a child during and up to 6 months after treatment. They should seek advice about sperm conservation prior to treatment with bendamustine hydrochloride because of possible irreversible infertility.</p><p><strong>Extravasation</strong></p><p>An extravasal injection should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit.</p><p><strong>Dilution</strong></p><p>Bendamustine requires appropriate dilution before use. The concentration of bendamustine in Bendamustine differs from other bendamustine products (see section 6.6 for further instructions on dilution).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No&nbsp;<em>in-vivo</em>&nbsp;interaction studies have been performed.</p><p>When bendamustine is combined with myelosuppressive agents, the effect of bendamustine and/or the co-administered medicinal products on the bone marrow may be potentiated. Any treatment reducing the patient&#39;s performance status or impairing bone marrow function can increase the toxicity of bendamustine.</p><p>Combination of bendamustine with cyclosporine or tacrolimus may result in excessive immunosuppression with risk of lymphoproliferation.</p><p>Cytostatics can reduce antibody formation following live-virus vaccination and increase the risk of infection which may lead to fatal outcome. This risk is increased in subjects who are already immunosuppressed by their underlying disease.</p><p>Bendamustine metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Therefore, potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir or cimetidine exists.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are insufficient data from the use of bendamustine in pregnant women. In nonclinical studies bendamustine hydrochloride was embryo-/fetolethal, teratogenic and genotoxic. During pregnancy bendamustine should not be used unless clearly necessary. The mother should be informed about the risk to the foetus. If treatment with bendamustine is absolutely necessary during pregnancy or if pregnancy occurs during treatment, the patient should be informed about the risks for the unborn child and be monitored carefully. The possibility of genetic counselling should be considered.</p><p><u>Fertility</u></p><p>Women of childbearing potential must use effective methods of contraception both before and during bendamustine therapy.</p><p>Men being treated with bendamustine are advised not to father a child during and for up to 6 months following cessation of treatment. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with bendamustine.</p><p><u>Breastfeeding</u></p><p>It is not known whether bendamustine passes into the breast milk, therefore, bendamustine is contraindicated during breastfeeding. Breastfeeding must be discontinued during treatment with bendamustine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bendamustine has major influence on the ability to drive and use machines. Ataxia, peripheral neuropathy and somnolence have been reported during treatment with bendamustine. Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most common adverse reactions with bendamustine hydrochloride are hematological adverse reactions (leukopenia, thrombopenia), dermatologic toxicities (allergic reactions), constitutional symptoms (fever), gastrointestinal symptoms (nausea, vomiting).</p><p>The table below reflects the data obtained with bendamustine hydrochloride.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p><p><strong>&ge;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge;1/100 to &lt;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge;1/1,000 to &lt;1/100</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>&ge;1/10,000 to &lt;1/1, 000</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p><strong>&lt;1/10, 000</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Infection NOS*, including opportunistic infection (e.g. Herpes zoster, cytomegalovirus, hepatitis B)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pneumocystis jirovecii pneumonia</p></td><td style="vertical-align:top"><p>Sepsis</p></td><td style="vertical-align:top"><p>Pneumonia primary atypical</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td><td style="vertical-align:top"><p>Myelodysplastic syndrome, Acute myeloid leukemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Leukopenia NOS*, Thrombocytopenia, Lymphopenia</p></td><td style="vertical-align:top"><p>Haemorrhage, Anaemia, Neut<u>r</u>openia</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td><td style="vertical-align:top"><p>Bone marrow failure</p></td><td style="vertical-align:top"><p>Haemolysis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity NOS*</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reaction, Anaphylactoid reaction</p></td><td style="vertical-align:top"><p>Anaphylactic shock</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Insomnia, Dizziness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Somnolence, Aphonia</p></td><td style="vertical-align:top"><p>Dysgeusia, Paraesthesia, Peripheral sensory neuropathy, Anticholinergic syndrome, Neurological disorders, Ataxia, Encephalitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cardiac dysfunction, such as palpitations, angina pectoris, Arrhythmia</p></td><td style="vertical-align:top"><p>Pericardial effusion, Myocardial infarction, Cardiac failure</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Atrial fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypotension, Hypertension</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Acute circulatory failure</p></td><td style="vertical-align:top"><p>Phlebitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pulmonary dysfunction</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Pulmonary fibrosis</p></td><td style="vertical-align:top"><p>Pneumonitis, Pulmonary alveolar haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, Vomiting</p></td><td style="vertical-align:top"><p>Diarrhoea, Constipation, Stomatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haemorrhagic oesophagitis, Gastrointestinal haemorrhage</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorder</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hepatic failure</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Alopecia, Skin disorders NOS*, Urticaria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Erythema, Dermatitis, Pruritus, Maculopapular rash, Hyperhidrosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Stevens &ndash; Johnson syndrome, Toxic Epidermal Necrolysis (TEN), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Renal failure</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Amenorrhea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Infertility</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Mucosal inflammation, Fatigue, Pyrexia</p></td><td style="vertical-align:top"><p>Pain, Chills, Dehydration, Anorexia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Multi organ failure</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Haemoglobin decrease, Creatinine increase, Urea increase</p></td><td style="vertical-align:top"><p>AST increase, ALT increase, Alkaline phosphatase increase, Bilirubin increase, Hypokalemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>NOS = Not otherwise specified</p><p>(*=combination therapy with rituximab)</p><p><u>Description of selected adverse reactions</u></p><p>There have been isolated reports of necrosis after accidental extra-vascular administration and tumour lysis syndrome, and anaphylaxis.</p><p>The risk of myelodysplastic syndrome and acute myeloid leukaemias is increased in patients treated with alkylating agents (including bendamustine). The secondary malignancy may develop several years after chemotherapy has been discontinued.</p><p><u>To reports any side effect(s):</u></p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After application of a 30 min infusion of bendamustine hydrochloride once every 3 weeks the maximum tolerated dose (MTD) was 280 mg/m<sup>2</sup>. Cardiac events of CTC grade 2 which were compatible with ischaemic ECG changes occurred which were regarded as dose limiting.</p><p>In a subsequent study with a 30 min infusion of bendamustine hydrochloride at day 1 and 2 every 3 weeks the MTD was found to be 180 mg/m<sup>2</sup>. The dose limiting toxicity was grade 4 thrombocytopenia. Cardiac toxicity was not dose limiting with this schedule.</p><p><em>Counter measures</em></p><p>There is no specific antidote. Bone marrow transplantation and transfusions (platelets, concentrated erythrocytes) may be made or haematological growth factors may be given as effective countermeasures to control haematological side effects.</p><p>Bendamustine hydrochloride and its metabolites are dialyzable to a small extent.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, alkylating agents,</p><p>ATC code: L01AA09</p><p>Bendamustine hydrochloride is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect of bendamustine hydrochloride is based essentially on a cross-linking of DNA single and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. The antitumour effect of bendamustine hydrochloride has been demonstrated by several&nbsp;<em>in vitro</em>&nbsp;studies in different human tumour cell lines (breast cancer, non-small cell and small cell lung cancer, ovary carcinoma and different leukaemia) and&nbsp;<em>in vivo</em>&nbsp;in different experimental tumour models with tumours of mouse, rat and human origin (melanoma, breast cancer, sarcoma, lymphoma, leukaemia and small cell lung cancer).</p><p>Bendamustine hydrochloride showed an activity profile in human tumour cell lines different to that of other alkylating agents. The active substance revealed no or very low cross-resistance in human tumour cell lines with different resistance mechanisms at least in part due to a comparatively persistent DNA interaction. Additionally, it was shown in clinical studies that there is no complete cross-resistance of bendamustine with anthracyclines, alkylating agents or rituximab. However, the number of assessed patients is small.</p><p><em>Chronic lymphocytic leukaemia</em></p><p>The indication for use in chronic lymphocytic leukaemia is supported by a single open label study comparing bendamustine with chlorambucil. In the prospective, multi-centre, randomised study, 319 previously untreated patients with chronic lymphocytic leukaemia stage Binet B or C requiring therapy were included. The first line therapy with bendamustine hydrochloride 100 mg/m<sup>2</sup>&nbsp;i.v. on days 1 and 2 (BEN) was compared to treatment with chlorambucil 0.8 mg/kg days 1 and 15 (CLB) for 6 cycles in both arms. Patients received allopurinol in order to prevent tumour lysis syndrome.</p><p>Patients with BEN have a significantly longer median progression free survival than patients with CLB treatment (21.5 versus 8.3 months, p &lt; 0.0001 in the latest follow-up). Overall survival was not statistically significantly different (median not reached). The median duration of remission is 19 months with BEN and 6 months with CLB treatment (p &lt; 0.0001). The safety evaluation in both treatment arms did not reveal any unexpected undesirable effects in nature and frequency. The dose of BEN was reduced in 34% of the patients. Treatment with BEN was discontinued in 3.9% of patients due to allergic reactions.</p><p><em>Indolent non-Hodgkin&#39;s lymphomas</em></p><p>The indication for indolent non-Hodgkin&#39;s lymphomas relied on two uncontrolled phase II trials.</p><p>In the pivotal prospective, multi-centre, open study 100 patients with indolent B-cell non-Hodgkin&acute;s lymphomas refractory to rituximab mono- or combination therapy were treated with BEN single agent. Patients received a median of 3 previous chemotherapy or biologic therapy courses. The median number of previous rituximab-containing courses was 2. The patients had had no response or progress within 6 months after rituximab treatment. The dose of BEN was 120 mg/m<sup>2</sup>&nbsp;i.v. on days 1 and 2 planned for at least 6 cycles. Duration of treatment depended on response (6 cycles planned). The overall response rate was 75% including 17% complete (CR and CRu) and 58% partial response as assessed by independent review committee. The median duration of remission was 40 weeks. BEN was generally well tolerated when given in this dose and schedule.</p><p>The indication is further supported by another prospective, multi-centre, open study including 77 patients. The patient population was more heterogeneous including: indolent or transformed B-cell non-Hodgkin&#39;s lymphomas refractory to rituximab mono- or combination therapy. The patients had no response or progress within 6 months or had had an untoward reaction to prior rituximab treatment. Patients received a median of 3 previous chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses was 2. The overall response rate was 76% with a median duration of response of 5 months (29 [95% CI 22.1, 43.1] weeks).</p><p><em>Multiple myeloma</em></p><p>In a prospective, multi-centre, randomised, open study 131 patients with advanced multiple myeloma (Durie-Salmon stage II with progress or stage III) were included. The first line therapy with bendamustine hydrochloride in combination with prednisone (BP) was compared to treatment with melphalan and prednisone (MP). Tolerability in both treatment arms was in line with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP arm.The dose was bendamustine hydrochloride 150 mg/m<sup>2</sup>&nbsp;i.v. on days 1 and 2 or melphalan 15 mg/m<sup>2</sup>&nbsp;i.v. on day 1 each in combination with prednisone. Duration of treatment depended on response and averaged 6.8 in the BP and 8.7 cycles in the MP group.</p><p>Patients with BP treatment have a longer median progression free survival than patients with MP (15 [95% CI 12-21] versus 12 [95% CI 10-14] months) (p=0.0566). The median time to treatment failure was 14 months with BP and 9 months with MP treatment. The duration of remission is 18 months with BP and 12 months with MP treatment. The difference in overall survival is not significantly different (35 months BP versus 33 months MP). Tolerability in both treatment arms was in line with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP arm.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Distribution</u></p><p>The elimination half-life t<sub>1/2&szlig;</sub>&nbsp;after 30 min i.v. infusion of 120 mg/m<sup>2</sup>&nbsp;area to 12 subjects was 28.2 minutes.</p><p>Following 30 min i.v. infusion the central volume of distribution was 19.3 l. Under steady-state conditions following i.v. bolus injection the volume of distribution was 15.8-20.5 l.</p><p>More than 95% of the substance is bound to plasma proteins (primarily albumin).</p><p><u>Biotransformation</u></p><p>A major route of clearance of bendamustine is the hydrolysis to monohydroxy- and dihydroxy-bendamustine. Formation of N-desmethyl-bendamustine and gamma-hydroxy-bendamustine by hepatic metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Another major route of bendamustine metabolism involves conjugation with glutathione.</p><p>In-vitro bendamustine does not inhibit CYP 1A4, CYP 2C9/10, CYP 2D6, CYP 2E1 and CYP 3A4.</p><p><u>Elimination</u></p><p>The mean total clearance after 30 min i.v. infusion of 120 mg/m<sup>2</sup>&nbsp;body surface area to 12 subjects was 639.4 ml/minute. About 20% of the administered dose was recovered in urine within 24 hours. Amounts excreted in urine were in the order monohydroxy-bendamustine &gt; bendamustine &gt; dihydroxy-bendamustine &gt; oxidised metabolite &gt; N-desmethyl bendamustine. In the bile, primarily polar metabolites are eliminated.</p><p><u>Hepatic impairment</u></p><p>In patients with 30 - 70% tumour infestation of the liver and mild hepatic impairment (serum bilirubin &lt; 1.2 mg/dl) the pharmacokinetic behaviour was not changed. There was no significant difference to patients with normal liver and kidney function with respect to C<sub>max</sub>, t<sub>max</sub>, AUC, t<sub>1/2&szlig;</sub>, volume of distribution and clearance. AUC and total body clearance of bendamustine correlate inversely with serum bilirubin.</p><p><u>Renal impairment</u></p><p>In patients with creatinine clearance &gt; 10 ml/min including dialysis dependent patients, no significant difference to patients with normal liver and kidney function was observed with respect to C<sub>max</sub>, t<sub>max</sub>, AUC, t<sub>1/2&szlig;</sub>, volume of distribution and clearance.</p><p><u>Elderly subjects</u></p><p>Subjects up to 84 years of age were included in pharmacokinetic studies. Higher age does not influence the pharmacokinetics of bendamustine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p>Histological investigations in dogs showed macroscopic visible hyperaemia of the mucosa and haemorrhagia in the gastrointestinal tract. Microscopic investigations showed extensive changes of the lymphatic tissue indicating an immunosuppression and tubular changes of kidneys and testis, as well as atrophic, necrotic changes of the prostate epithelium.</p><p>Animal studies showed that bendamustine is embryotoxic and teratogenic.</p><p>Bendamustine induces aberrations of the chromosomes and is mutagenic&nbsp;<em>in vivo</em>&nbsp;as well as&nbsp;<em>in vitro</em>. In long-term studies in female mice bendamustine is carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Butylhydroxytoluene</p><p>Macrogol 300</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
The concentrate should be diluted with 0.9% sodium chloride solution.
After opening of the vial
Chemical and physical in use stability has been demonstrated for 28 days at 2°– 8°C.
From a microbiological point of view, once opened the product may be stored for a maximum of 28 days at 2°– 8°C. Other in-use storage times and conditions are the responsibility of the user.
Solution for infusion
After dilution, chemical and physical stability has been demonstrated for 3.5 hours at 25°C/60% RH and 2 days at 2°C– 8°C in polyethylene bags.
From a microbiological point of view, the solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Minimisation of the risk of contamination of the multidose vial during withdrawal of each dose is the responsibility of the user. Record date and time of the first dose withdrawal on the vial label. Between uses, return the multidose vial to the recommended storage condition of 2°– 8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2 &ndash; 8&deg;C). Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>For storage conditions of the diluted medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I amber glass vial 5 ml with 20 mm rubber stopper and 20 mm flip-off seal.</p><p>Pack sizes of 1 vial.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When handling Ensutine, inhalation, skin contact or contact with mucous membranes should be avoided (wear gloves and protective clothes!). Contaminated body parts should be carefully rinsed with water and soap, the eyes should be rinsed with physiological saline solution. If possible it is recommended to work on special safety workbenches (laminar flow) with liquid-impermeable, absorbent disposable foil. Pregnant personnel should be excluded from handling cytostatics.</p><p>The concentrate for solution for infusion has to be diluted with sodium chloride 9 mg/ml (0.9%) solution for injection and then administered by intravenous infusion. Aseptic technique is to be used.</p><p><u>1. Dilution</u></p><p>Aseptically withdraw the volume needed for the required dose from the Ensutine 180 mg/4 ml vial. Dilute the total recommended dose of Ensutine 180 mg/4 ml with 0.9% sodium chloride solution to produce a final volume of about 500 ml.</p><p>While diluting the product it should be noted that the concentration (45 mg/ml) of bendamustine in Bendamustine is higher than in usual bendamustine concentrates resulting from reconstitution of bendamustine powder containing medicinal products.</p><p>Ensutine 180 mg/4 ml must be diluted with 0.9% NaCl solution and not with any other injectable solutions.</p><p><u>2. Administration</u></p><p>The solution is administered by intravenous infusion over 30-60 min.</p><p>The vials are for multiple dose use.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad Road, Al Mohammadiyah Dist.
Building no.8006,4th floor, office no.32, unit no.9
Riyadh, Saudi Arabia
Tel: +966-11- 920001432
Fax: +966-11- 4622230
Email: info@sudairpharma.com
Mailing: P.O. Box 12363 Riyadh4432, Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                06/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>